Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover

Osteoarthritis and Cartilage

Volumn 22, Issue 1, 2014, Pages 44-50

  Siebuhr, A S ^a   Petersen, K K ^b,d   Arendt Nielsen, L ^b   Egsgaard, L L ^b   Eskehave, T ^c   Christiansen, C ^a,c   Simonsen, O ^d   Hoeck, H C ^c   Karsdal, M A ^a   Bay Jensen, A C ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biochemical markers of inflammation and collagen turnover; Inflammation; Matrix metalloproteinases; Osteoarthritis; Selection of the right patients for the right treatment

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN DEGRADATION; REFERENCE VALUE; TOTAL KNEE REPLACEMENT; TURNOVER TIME; YOUNG ADULT;

BIOCHEMICAL MARKERS OF INFLAMMATION AND COLLAGEN TURNOVER; INFLAMMATION; MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; SELECTION OF THE RIGHT PATIENTS FOR THE RIGHT TREATMENT;

AGED; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL MARKERS; COLLAGEN TYPE I; COLLAGEN TYPE II; COLLAGEN TYPE III; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; OSTEOARTHRITIS, KNEE; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; SYNOVITIS;

EID: 84891747477     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2013.10.020     Document Type: Article

References (35)

1. Bay-Jensen A.C., Hoegh-Madsen S., Dam E., Henriksen K., Sondergaard B.C., Pastoureau P., et al. Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?. Rheumatol Int 2010, 30:435-442.
2. Bay-Jensen A.C., Platt A., Byrjalsen I., Vergnoud P., Christiansen C., Karsdal M.A. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin Arthritis Rheum 2013.
3. Scanzello C.R., McKeon B., Swaim B.H., Dicarlo E., Asomugha E.U., Kanda V., et al. Synovial inflammation in patients undergoing arthroscopic meniscectomy: molecular characterization and relationship to symptoms. Arthritis Rheum 2011, 63:391-400.
4. Goldring M.B., Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011, 23:471-478.
5. Bejon P., Byren I., Atkins B.L., Scarborough M., Woodhouse A., Lardy-Smith P., et al. Serial measurement of the C-reactive protein is a poor predictor of treatment outcome in prosthetic joint infection. JAntimicrob Chemother 2011, 66:1590-1593.
6. Dolzani P., Assirelli E., Pulsatelli L., Addimanda O., Mancarella L., Peri G., et al. Systemic inflammation and antibodies to citrullinated peptides in hand osteoarthritis. Clin Exp Rheumatol 2011, 29:1006-1009.
7. Rhodes B., Furnrohr B.G., Vyse T.J. C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 2011, 7:282-289.
8. Karsdal M.A., Henriksen K., Leeming D.J., Woodworth T., Vassiliadis E., Bay-Jensen A.C. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers - are they the cause or the consequence of the disease?. Clin Biochem 2010, 43:793-804.
9. Skjot-Arkil H., Schett G., Zhang C., Larsen D.V., Wang Y., Zheng Q., et al. Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin Exp Rheumatol 2012, 30:371-379.
10. Ayral X., Pickering E.H., Woodworth T.G., Mackillop N., Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 2005, 13:361-367.
11. Appleton C.T., Pitelka V., Henry J., Beier F. Global analyses of gene expression in early experimental osteoarthritis. Arthritis Rheum 2007, 56:1854-1868.
12. Burrage P.S., Mix K.S., Brinckerhoff C.E. Matrix metalloproteinases: role in arthritis. Front Biosci 2006, 11:529-543.
13. Rousseau J.C., Delmas P.D. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 2007, 3:346-356.
14. Bay-Jensen A.C., Sondergaard B.C., Christiansen C., Karsdal M.A., Madsen S.H., Qvist P. Biochemical markers of joint tissue turnover. Assay Drug Dev Technol 2010, 8:118-124.
15. Qvist P., Bay-Jensen A.C., Christiansen C., Sondergaard B.C., Karsdal M.A. Molecular serum and urine marker repertoire supporting clinical research on joint diseases. Best Pract Res Clin Rheumatol 2011, 25:859-872.
16. Barascuk N., Vassiliadis E., Larsen L., Wang J., Zheng Q., Xing R., et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of a specific MMP-9 mediated degradation fragment of type III collagen - a novel biomarker of atherosclerotic plaque remodeling. Clin Biochem 2011, 44:900-906.
17. Bay-Jensen A.C., Liu Q., Byrjalsen I., Li Y., Wang J., Pedersen C., et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM - increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 2011, 44:423-429.
18. Leeming D., He Y., Veidal S., Nguyen Q., Larsen D., Koizumi M., et al. Anovel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011, 16:616-628.
19. Hill C.L., Gale D.G., Chaisson C.E., Skinner K., Kazis L., Gale M.E., et al. Knee effusions, popliteal cysts, and synovial thickening: association with knee pain in osteoarthritis. JRheumatol 2001, 28:1330-1337.
20. Siebuhr A.S., Wang J., Karsdal M., Bay-Jensen A.C., Y J., Q Z. Matrix metalloproteinase-dependent turnover of cartilage, synovial membrane, and connective tissue is elevated in rats with collagen induced arthritis. JTransl Med 2012, 10:195.
21. Garnero P., Ferreras M., Karsdal M.A., Nicamhlaoibh R., Risteli J., Borel O., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. JBone Miner Res 2003, 18:859-867.
22. Garnero P., Delmas P.D. Biomarkers in osteoarthritis. Curr Opin Rheumatol 2003, 15:641-646.
23. Garnero P., Conrozier T., Christgau S., Mathieu P., Delmas P.D., Vignon E. Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis 2003, 62:939-943.
24. Karsdal M.A., Byrjalsen I., Bay-Jensen A.C., Henriksen K., Riis B.J., Christiansen C. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis - the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord 2010, 11:125.
25. Syversen S.W., Haavardsholm E.A., Boyesen P., Goll G.L., Okkenhaug C., Gaarder P.I., et al. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann Rheum Dis 2010, 69:845-850.
26. Nemirovskiy O.V., Dufield D.R., Sunyer T., Aggarwal P., Welsch D.J., Mathews W.R. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from invitro to invivo. Anal Biochem 2007, 361:93-101.
27. Siebuhr A.S., Bay-Jensen A.C., Leeming D.J., Platt A., Byrjalsen I., Christiansen C., et al. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther 2013, 15:R86.
28. Bay-Jensen A.C., Wichuk S., Byrjalsen I., Leeming D.J., Morency N., Christiansen C., et al. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS One 2013, 8:e54504.
29. Vassiliadis E., Larsen D.V., Clausen R.E., Veidal S.S., Barascuk N., Larsen L., et al. Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbon-tetrachloride-induced fibrosis. Biomark Insights 2011, 6:49-58.
30. Vassiliadis E., Veidal S.S., Barascuk N., Mullick J.B., Clausen R.E., Larsen L., et al. Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol 2011, 11:6.
31. Veidal S.S., Vassiliadis E., Barascuk N., Zhang C., Segovia-Silvestre T., Klickstein L., et al. Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int 2010, 30:1293-1304.
32. Tan P.L., Farmiloe S., Yeoman S., Watson J.D. Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. JRheumatol 1990, 17:1608-1612.
33. Miossec P., Briolay J., Dechanet J., Wijdenes J., Martinez-Valdez H., Banchereau J. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an exvivo model of rheumatoid synovitis. Arthritis Rheum 1992, 35:874-883.
34. Koch A.E., Kunkel S.L., Chensue S.W., Haines G.K., Strieter R.M. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol 1992, 65:23-29.
35. Kay J., Upchurch K.S. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 2012, 51(Suppl 6):vi5-vi9.